# Ibogaine Psychiatric Research 2026: Latest Clinical Insights > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ibogaine-psychiatric-research-2026/ > **Published:** 2026-04-23T13:28:49-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:14:21-04:00 > **Clinical Summary:** Explore ibogaine psychiatric research 2026 and its evolving role alongside cannabis policy and clinical updates in this April 23, 2026 article digest. --- In the Mix — Last 24 HoursApril 23, 2026. 4 articles reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score. #25 [Tennessee bans THC and kratom, pursues study of Ibogaine – Nashville Banner](https://nashvillebanner.com/2026/04/23/tennessee-legilsation-thc-kratom-ibogaine-vapes/) Tennessee enacted bans on THC and kratom while initiating research into ibogaine’s psychiatric potential, reflecting evolving state drug policy approaches relevant to cannabis regulation contexts. [Read more →](https://nashvillebanner.com/2026/04/23/tennessee-legilsation-thc-kratom-ibogaine-vapes/) #15 [The best CBD gummies for ED](https://www.qsr.mlit.go.jp/kikuti/pannellum/pannellum.htm?config=/%5C/ccc1.sbs/article/cbd2/0nmSvM) This article reviews CBD gummy products marketed for erectile dysfunction, noting reported relaxation effects attributed to [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) interaction. [Read more →](https://www.qsr.mlit.go.jp/kikuti/pannellum/pannellum.htm?config=/%5C/ccc1.sbs/article/cbd2/0nmSvM) #5 [Excessive napping in older adults may signal serious health issues, study finds | WJHL](https://www.wjhl.com/news/national/excessive-napping-in-older-adults-may-signal-serious-health-issues-study-finds/) This article examines excessive daytime napping in older adults as a potential health indicator, which may interest clinicians treating cannabis patients managing sleep disorders or age-related conditions. [Read more →](https://www.wjhl.com/news/national/excessive-napping-in-older-adults-may-signal-serious-health-issues-study-finds/) #2 [Tenet Healthcare (THC) Expected to Beat Earnings Estimates: Should You Buy? – April 23, 2026](https://www.zacks.com/stock/news/2906647/tenet-healthcare-thc-expected-to-beat-earnings-estimates-should-you-buy) This article discusses Tenet Healthcare’s financial performance expectations; it may interest cannabis clinicians only as a reminder to verify ticker symbols when researching cannabis-related companies versus unrelated healthcare corporations. [Read more →](https://www.zacks.com/stock/news/2906647/tenet-healthcare-thc-expected-to-beat-earnings-estimates-should-you-buy) Digest-Level Clinical Commentary Dr. Caplan’s Take These items underscore three distinct pressures shaping contemporary [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/): the regulatory uncertainty created by state-level prohibition despite emerging research interest in cannabinoids for psychiatric conditions, the commercial proliferation of unregulated [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) making therapeutic claims without robust clinical evidence, and the importance of distinguishing [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) discussions from unrelated health topics and financial news that happen to share acronyms. As practitioners, we must remain grounded in evidence-based prescribing while acknowledging that legitimate therapeutic investigation into cannabinoids continues even in prohibitionist jurisdictions, and we should be cautious about patient reliance on over-the-counter formulations lacking standardization or clinical validation. Clinical Perspective These items illustrate the fragmented landscape of cannabis policy and research in the United States, where regulatory approaches vary widely by state despite ongoing scientific interest in cannabinoid therapeutics. The inclusion of a financial article about Tenet Healthcare demonstrates how cannabis-related acronyms create confusion in public discourse, potentially obscuring substantive clinical discussions about cannabinoid safety and efficacy. Overall, the digest reflects an emerging but still preliminary evidence base for cannabinoid applications, alongside persistent regulatory barriers that limit rigorous clinical investigation in most jurisdictions. Cannabis PolicyCannabinoidsRegulatory NewsHealth ResearchWellness Products 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+In+the+Mix+%E2%80%94+April+23%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+In+the+Mix+%E2%80%94+April+23%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [In the Mix: 7 More Articles — April 24, 2026](https://cedclinic.com/cannabinoid-clinical-research-updates-2026-april-24/) Continue exploring recent clinical and policy updates in cannabis and related drug research with this April 24, 2026 article digest. [Read More](https://cedclinic.com/cannabinoid-clinical-research-updates-2026-april-24/) Trump’s DOJ Issues New Rescheduling Order – CRB Monitor News Stay informed on recent federal regulatory changes impacting cannabis and related substances with this detailed news update. Learn More [Cannabis Terpenes Enhance THC's Activation of Cannabinoid Receptors, Study Finds](https://cedclinic.com/cannabis-terpenes-enhance-thcs-activation-of-cannabinoid-receptors-study-finds-2/) Discover new research on how [cannabis terpenes](https://cedclinic.com/s-caryophyllene-a-terpine-found-in-cannabis-demonstrates-therapeutic-potential-in-a-mouse-model-of-ms/) influence cannabinoid receptor activation and therapeutic potential. [Explore Study](https://cedclinic.com/cannabis-terpenes-enhance-thcs-activation-of-cannabinoid-receptors-study-finds-2/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).